Key Points
- CEO Snehal Patel bought 4,600 shares on Nov. 25 at an average price of $8.37, bringing his direct ownership to 5,588,102 shares (≈$46.8M) after earlier purchases of 10,600 on Nov. 7 and 2,300 on Oct. 31.
- Shares trade near $8.86 (1‑year range $7.78–$15.47) with a market cap of about $122.7M, while analysts show a consensus Hold but an average target price of $42.
- Greenwich LifeSciences is a clinical‑stage biotech developing the immunotherapy GP2, which is in a Phase III trial to prevent breast cancer recurrence.
Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel bought 4,600 shares of the business's stock in a transaction dated Tuesday, November 25th. The stock was acquired at an average cost of $8.37 per share, for a total transaction of $38,502.00. Following the completion of the acquisition, the chief executive officer directly owned 5,588,102 shares in the company, valued at approximately $46,772,413.74. This trade represents a 0.08% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Snehal Patel also recently made the following trade(s):
- On Friday, November 7th, Snehal Patel purchased 10,600 shares of Greenwich LifeSciences stock. The shares were acquired at an average price of $8.43 per share, with a total value of $89,358.00.
- On Friday, October 31st, Snehal Patel acquired 2,300 shares of Greenwich LifeSciences stock. The stock was acquired at an average price of $9.26 per share, for a total transaction of $21,298.00.
Greenwich LifeSciences Stock Performance
Shares of NASDAQ:GLSI opened at $8.86 on Friday. Greenwich LifeSciences, Inc. has a one year low of $7.78 and a one year high of $15.47. The stock has a market capitalization of $122.70 million, a price-to-earnings ratio of -6.07 and a beta of 1.61. The company has a 50-day simple moving average of $9.45 and a 200-day simple moving average of $10.23.
Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.30). As a group, research analysts forecast that Greenwich LifeSciences, Inc. will post -0.8 EPS for the current fiscal year.
Institutional Investors Weigh In On Greenwich LifeSciences
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in shares of Greenwich LifeSciences by 4.9% during the 3rd quarter. Vanguard Group Inc. now owns 282,181 shares of the company's stock worth $2,808,000 after acquiring an additional 13,179 shares in the last quarter. Geode Capital Management LLC raised its holdings in Greenwich LifeSciences by 1.4% during the second quarter. Geode Capital Management LLC now owns 138,982 shares of the company's stock worth $1,261,000 after purchasing an additional 1,972 shares during the last quarter. Marshall Wace LLP purchased a new stake in Greenwich LifeSciences during the second quarter worth $509,000. Citadel Advisors LLC boosted its position in Greenwich LifeSciences by 52.1% during the third quarter. Citadel Advisors LLC now owns 20,942 shares of the company's stock worth $208,000 after purchasing an additional 7,174 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Greenwich LifeSciences by 15.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 19,007 shares of the company's stock valued at $181,000 after purchasing an additional 2,552 shares during the last quarter. 4.16% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several research firms have recently commented on GLSI. Noble Financial started coverage on Greenwich LifeSciences in a research note on Wednesday, August 20th. They set an "outperform" rating and a $45.00 price target for the company. Weiss Ratings reissued a "sell (e+)" rating on shares of Greenwich LifeSciences in a research note on Tuesday, October 14th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $42.00.
Get Our Latest Stock Analysis on Greenwich LifeSciences
Greenwich LifeSciences Company Profile
(
Get Free Report)
Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
